Virus filtration is a robust and effective virus clearance technology that is common unit operation in the manufacture of biologics. Some biological therapeutic products are produced using mammalian cell lines or human plasma. The risk of contamination with either known or unknown viruses in these products has been demonstrated; hence, regulatory agencies have mandated that manufacturers evaluate the risks of virus contamination and take necessary measures to mitigate these risks.
Key factors driving the market are rapid growth of pharmaceutical and biotechnology industry, increasing investments in R&D and outsourcing activities are key drivers for the growth of the market. The report would be of an interest to various stakeholders operating in the virus filtration market. These stakeholders include healthcare institutes, contract research organizations (CROs), research institutes, virus filtration product manufacturers and vendors, research consulting firms, virus filtration service providers, distributors and others.
The major players operating in the Study
1. Merck KGaA
2. Sartorius AG
3. Danaher (Pall Corporation)
4. Thermo Fisher Scientific, Inc.
5. General Electric
6. Charles River
7. Wuxi Apptec
9. Asahi Kesai Corporation
10. Clean Cells
The company players are indulged into development of novel and innovative products to cater the demands of users in the virus filtration market. For instance, in June 2016, Sartorius Stedim Biotech (SSB), a sub-division of Sartorius AG introduced a new virus-retentive filter to be used in the cell culture media. The new filter provides the highest level of safety for customers’ upstream processes. This launch is expected to compliment and increase the bioprocess portfolio of Sartorius.